import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "weight-based-peptide-dosing-research-protocol-design-ovn18",
  title: "Weight-Based Peptide Dosing: Research Protocol Design and Allometric Scaling",
  description:
    "How to design weight-based dosing protocols for peptide research, scale between species using allometric equations, calculate reconstitution volumes, and structure dose-response studies. A practical reference for preclinical researchers.",
  category: "Research Protocols",
  readMinutes: 12,
  publishedAt: "2026-06-22",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Dosing errors are a leading source of variability in peptide research. A protocol that specifies 5 mg/kg in a mouse model, translated naively to a 70 kg human without allometric correction, produces a dose that may be either ineffective or potentially unsafe. Rigorous peptide dosing protocol design requires understanding of allometric scaling, body weight calculation, reconstitution math, and the statistical considerations that determine whether a dose-response study will have adequate power to detect meaningful effects.",
    },
    {
      type: "heading",
      text: "Why Weight-Based Dosing Matters",
    },
    {
      type: "paragraph",
      text: "In contrast to fixed-dose drug administration, weight-based (mg/kg) dosing normalizes for inter-animal variability in body weight, ensuring that each subject in a study receives a dose proportional to its metabolizing mass. For peptides, which are rapidly cleared by proteases and renal filtration, this normalization is particularly important because clearance rates scale roughly with body weight.",
    },
    {
      type: "list",
      items: [
        "mg/kg dosing: dose in milligrams divided by animal body weight in kilograms",
        "μg/kg dosing: used for high-potency peptides (some GH secretagogues, kisspeptin); 1000 μg = 1 mg",
        "nmol/kg dosing: molar dosing; useful for mechanistic comparisons across peptides of different MW",
        "Fixed dose: appropriate only when variability in body weight is minimal and PK is non-linear",
      ],
    },
    {
      type: "heading",
      text: "Step-by-Step: Calculating Injection Volume",
    },
    {
      type: "paragraph",
      text: "A research team using a 5 mg/kg IP dose of BPC-157 in a 250 g rat with a 1 mg/mL stock solution needs to calculate how many mL to inject. The formula:",
    },
    {
      type: "callout",
      text: "Injection Volume (mL) = [Dose (mg/kg) × Body Weight (kg)] ÷ Stock Concentration (mg/mL)\n\nExample: 5 mg/kg × 0.250 kg ÷ 1 mg/mL = 1.25 mL",
    },
    {
      type: "paragraph",
      text: "For IP injection in rats, 1–5 mL is the practical range. For SC injection, ≤2 mL per site is preferred. For mice (20–30 g), volumes should be much smaller — typically 0.1–0.3 mL IP and 0.05–0.1 mL SC. Adjust stock concentration to stay within practical injection volumes.",
    },
    {
      type: "table",
      headers: ["Species", "Body Weight Range", "Max IP Volume", "Max SC Volume (per site)", "Max IV Volume"],
      rows: [
        ["Mouse", "20–35 g", "2 mL/kg (0.04–0.07 mL)", "10 mL/kg (0.02–0.035 mL)", "5 mL/kg"],
        ["Rat", "200–400 g", "10 mL/kg (2–4 mL)", "5 mL/kg (1–2 mL)", "5 mL/kg"],
        ["Rabbit", "2–4 kg", "20 mL/kg", "1 mL/site", "2 mL/kg"],
        ["Guinea pig", "300–600 g", "10 mL/kg", "5 mL/kg", "4 mL/kg"],
      ],
    },
    {
      type: "heading",
      text: "Allometric Scaling Between Species",
    },
    {
      type: "paragraph",
      text: "Allometric scaling uses the relationship between body weight and physiological parameters (metabolic rate, organ size, clearance) to translate doses between species. The standard allometric equation is:",
    },
    {
      type: "callout",
      text: "Human Equivalent Dose (mg/kg) = Animal Dose (mg/kg) × (Animal Km / Human Km)\n\nKm values: Mouse = 3, Rat = 6, Rabbit = 12, Monkey = 37, Human = 37\n\nExample: Mouse dose 10 mg/kg → Human Equivalent = 10 × (3/37) ≈ 0.81 mg/kg",
    },
    {
      type: "paragraph",
      text: "The Km factor (body weight in kg / body surface area in m²) accounts for the fact that metabolic rate scales with body surface area, not body weight. Smaller animals have a higher surface area-to-weight ratio and therefore higher metabolic rates per kg — which is why mouse doses in mg/kg are typically much higher than human doses for the same compound.",
    },
    {
      type: "table",
      headers: ["Species", "Weight (kg)", "BSA (m²)", "Km Factor"],
      rows: [
        ["Mouse", "0.02", "0.007", "3"],
        ["Rat", "0.15", "0.025", "6"],
        ["Rabbit", "1.8", "0.15", "12"],
        ["Macaque", "3.0", "0.24", "12"],
        ["Rhesus monkey", "5.0", "0.40", "12.3"],
        ["Marmoset", "0.35", "0.06", "6"],
        ["Human (adult)", "60", "1.62", "37"],
      ],
    },
    {
      type: "heading",
      text: "Body Weight Normalization in Chronic Studies",
    },
    {
      type: "paragraph",
      text: "In chronic studies where body weight changes over time (e.g., obesity models, anabolic peptide studies), dosing should be recalculated at regular intervals based on current body weight. Failure to adjust for weight gain in high-fat diet studies can result in effective dose reductions of 20–40% over an 8-week protocol.",
    },
    {
      type: "list",
      items: [
        "Weigh animals at minimum: weekly for 4-week studies; twice weekly for 8-week+ studies",
        "Recalculate injection volumes at each weigh-in using updated body weights",
        "Document body weight at each dosing point — critical for data integrity and reproducibility",
        "Use calibrated digital balances (readability ≤0.1 g for mice, ≤1 g for rats)",
        "In obese models: consider whether dosing to total body weight or lean body mass is mechanistically appropriate",
      ],
    },
    {
      type: "heading",
      text: "Dose-Response Study Design",
    },
    {
      type: "paragraph",
      text: "A well-designed dose-response study establishes the relationship between dose level and effect magnitude, allowing identification of the minimum effective dose (MED), the ED₅₀ (dose producing 50% of maximal effect), and the no observed adverse effect level (NOAEL). For peptide research, a minimum of 3–4 dose levels plus vehicle control is recommended.",
    },
    {
      type: "table",
      headers: ["Group", "Treatment", "Purpose"],
      rows: [
        ["1", "Vehicle control (0 mg/kg)", "Establish baseline / spontaneous variation"],
        ["2", "Low dose (0.1× expected therapeutic)", "Establish subthreshold; detect unexpected low-dose effects"],
        ["3", "Mid-low dose (0.3–0.5× expected)", "Approach MED"],
        ["4", "Mid dose (1× expected therapeutic)", "Primary efficacy dose"],
        ["5", "High dose (3–10× expected)", "Test for toxicity; confirm plateau of dose-response curve"],
      ],
    },
    {
      type: "subheading",
      text: "Spacing Dose Levels",
    },
    {
      type: "paragraph",
      text: "Use log-scale spacing (e.g., 0.1, 0.3, 1.0, 3.0, 10 mg/kg) rather than linear spacing (1, 2, 3, 4, 5 mg/kg). Log spacing provides better coverage of the dose-response curve, which is sigmoidal on a log scale, and is consistent with pharmacological convention for receptor-mediated effects.",
    },
    {
      type: "heading",
      text: "Reconstitution Math and Stock Preparation",
    },
    {
      type: "paragraph",
      text: "Accurate stock solution preparation is the foundation of reproducible dosing. Starting from a lyophilized peptide:",
    },
    {
      type: "callout",
      text: "Volume to Add (mL) = Mass of Peptide (mg) ÷ Target Concentration (mg/mL)\n\nExample: 10 mg vial, target 2 mg/mL → Add 5 mL sterile vehicle",
    },
    {
      type: "list",
      items: [
        "Use sterile PBS (pH 7.4) or sterile water as default vehicle — verify peptide solubility first",
        "For poorly water-soluble peptides: try 0.9% saline → 10 mM phosphate buffer → 5% dextrose → 10% DMSO:saline (last resort for IP/SC only)",
        "Prepare stock at 10–100× working concentration to allow serial dilution for dose-response studies",
        "Vortex gently; do not sonicate high-MW peptides",
        "Check visual clarity after reconstitution — turbidity indicates incomplete dissolution or aggregation",
        "Aliquot immediately into single-use volumes to avoid repeated freeze-thaw of stock",
        "Label: compound, concentration, solvent, date, prep batch, stored by",
      ],
    },
    {
      type: "heading",
      text: "Calculating Group Sizes: Statistical Power",
    },
    {
      type: "paragraph",
      text: "Underpowered studies are the single most common methodological flaw in peptide research publications. Power analysis should be performed before the study, using pilot data or published effect sizes from comparable studies to estimate the expected difference and standard deviation.",
    },
    {
      type: "list",
      items: [
        "Target statistical power: ≥80% (β = 0.2); 90% preferred for mechanistic studies",
        "Significance threshold: α = 0.05 (two-tailed) standard; α = 0.01 for dose-toxicity studies",
        "Effect size: obtain from published data or pilot; if unavailable, Cohen's d = 0.5–0.8 is typical for peptide interventions in rodent models",
        "Use G*Power (free) or R's 'pwr' package for power calculations",
        "For behavioral endpoints (MWM, NOR): typically n = 8–12/group",
        "For biochemical endpoints (ELISA, Western blot): typically n = 6–8/group",
        "For histology: n = 4–6/group (can overlap with biochemistry animals)",
      ],
    },
    {
      type: "heading",
      text: "Common Dosing Errors and How to Avoid Them",
    },
    {
      type: "table",
      headers: ["Error", "Consequence", "Prevention"],
      rows: [
        ["Using body weight in grams instead of kg", "100× overdose or underdose", "Always convert to kg before calculation; double-check units"],
        ["Forgetting to adjust concentration for purity (e.g., 85% peptide content)", "Systematic underdosing", "Calculate effective peptide mass: mass × purity fraction"],
        ["Not accounting for salt form (acetate vs. TFA)", "MW-based dosing error", "Confirm free base MW vs. salt MW with supplier; use molar dosing when salt form varies"],
        ["Reconstituting to wrong volume", "All downstream doses wrong", "Calculate volume needed, measure with calibrated pipette, record batch prep"],
        ["Not filtering reconstituted stock (0.2 μm)", "Introducing particles or microbes", "Filter all stocks intended for in vivo use through sterile 0.22 μm membrane"],
        ["Mixing incompatible vehicles", "Precipitation; reduced bioavailability", "Test vehicle compatibility in small test volume before scale-up"],
      ],
    },
    {
      type: "heading",
      text: "Practical Protocol Documentation Template",
    },
    {
      type: "paragraph",
      text: "A complete dosing protocol documentation entry should include all variables needed for full reproducibility:",
    },
    {
      type: "list",
      items: [
        "Compound: name, CAS number, molecular weight (free base and salt form)",
        "Supplier, lot number, purity by HPLC, CoA date",
        "Stock concentration and vehicle preparation method",
        "Target dose (mg/kg or μg/kg), route, frequency, duration",
        "Injection volume per animal weight band (e.g., per 50 g increment)",
        "Storage conditions for stock and working solutions",
        "Date of reconstitution; expiry date of working aliquots",
        "Blinding method (if applicable) and who prepared vs. administered",
        "Body weight monitoring schedule and dose adjustment decision rules",
      ],
    },
    {
      type: "disclaimer",
      text: "All dosing information is provided for preclinical research design purposes. Peptide compounds discussed are research-grade materials not approved for human use. Allometric scaling provides theoretical estimates only; actual human pharmacokinetics require dedicated clinical PK studies.",
    },
  ],
};
